جميع الدراسات
نشط غير مجندالمرحلة 3تدخلي

دراسة لمقارنة فعالية وسلامة لوسباتيرسيبت (ACE-536) مقابل إيبويتين ألفا لعلاج فقر الدم الناتج عن متلازمات خلل التنسج النقوي (MDS) ذات المخاطر المنخفضة جدًا، المنخفضة، أو المتوسطة وفقًا لنظام IPSS-R للمشاركين الذين يحتاجون إلى نقل خلايا الدم الحمراء ولم يتلقوا علاج ESA من قبل

This research is looking at two different medicines, luspatercept and epoetin alfa, to treat a blood condition called myelodysplastic syndromes (MDS). People with MDS often have low red blood cell counts (anemia) and need regular blood transfusions. The main goal of this study is to find out if luspatercept is better than epoetin alfa at helping people become transfusion-independent, meaning they no longer need regular blood transfusions, and if it can also increase their red blood cell levels. The study focuses on people with specific types of MDS risk who haven't tried similar treatments before.

نظرة سريعة

الحالة
نشط غير مجند
المرحلة
المرحلة 3
الراعي
Celgene
الهدف من التسجيل
363
ابدأ
02 Jan 2019
التاريخ المتوقع للانتهاء
28 Sep 2027

النتائج

نتائج هذه الدراسة

تم النشر June 2024

تم نشر نتائج هذه الدراسة.

النتيجة الأساسية
Percentage of Participants With Red Blood Cell Transfusion Independence (RBC-TI) for 12 Weeks (84 Days) With a Mean Hemoglobin Increase ≥ 1.5 g/dL
Percentage of participants who are RBC transfusion-free for any 12-week period associated with a concurrent mean hemoglobin (Hgb) increase ≥ 1.5 g/dL compared to baseline. After applying below 14/3-day rule, the baseline Hgb value is defined as the lowest Hgb value from the central, local laboratory, or pre transfusion Hgb from transfusion records that is within 56 days on or prior to the first dose of treatment, or randomization date if participants were not treated. 4/3-day rule: only Hgb values that are at least 14 days after a transfusion may be used unless there is another transfusion within 3 days after the Hgb assessment. If this occurs, that Hgb value will be used despite being \< 14 days after the previous transfusion.
النتائج الكاملة في السجل

ما هو موضوع هذه الدراسة؟

You're reading about a research study for people with a blood condition called myelodysplastic syndromes, or MDS. MDS affects your bone marrow, which is the soft, spongy tissue inside your bones where new blood cells are made. In MDS, the bone marrow doesn't produce enough healthy blood cells, especially red blood cells. When you don't have enough healthy red blood cells, you can develop a condition called anemia, which can make you feel very tired and weak, and you might need regular blood transfusions.

This study is comparing two different medicines: luspatercept (sometimes called ACE-536) and epoetin alfa. Epoetin alfa is a common treatment that helps your body make more red blood cells. Luspatercept is a newer medicine, and researchers want to see if it works better than epoetin alfa. The main aim is to see if these medicines can help people with MDS stop needing blood transfusions for at least 12 weeks, and also increase their red blood cell count.

This is a 'Phase 3' study, which means it's one of the final steps in testing a new medicine to make sure it's both safe and effective before it can be widely used. Taking part in a study like this helps doctors learn more about the best ways to treat MDS, which can benefit many people in the future.

النقاط الرئيسية

  • This study compares luspatercept and epoetin alfa for MDS.
  • The main goal is to reduce the need for blood transfusions.
  • It's a Phase 3 study, meaning it's a final step in testing a new medicine.
  • You will receive regular check-ups and blood tests if you participate.
  • Participation could help improve future treatments for MDS.
  • يمكنك التوقف عن المشاركة في أي وقت دون التأثير على رعايتك.

من قد يكون مؤهلاً؟

To join this study, doctors will first check if you have myelodysplastic syndromes (MDS) and if your condition is considered 'very low', 'low', or 'intermediate' risk. This is based on specific criteria that doctors use to classify MDS. An important part of joining is that you must be needing regular red blood cell transfusions. Specifically, you would have received between two and six units of blood every eight weeks for at least two months before the study starts. You also shouldn't have tried treatments like epoetin alfa before.

There are also some reasons why you might not be able to join. For example, if your anemia is caused by other easily treatable things like a lack of iron or vitamins, or if you have certain other serious health problems. You also wouldn't be able to join if you have a known history of acute myeloid leukaemia (AML) or if your blood pressure is not well controlled even with medication. The medical team will check all these carefully with you.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. I have been diagnosed with MDS.
  2. My MDS is classified as 'very low', 'low', or 'intermediate' risk.
  3. I currently need regular red blood cell transfusions (2-6 units every 8 weeks).
  4. I have not previously taken similar medications like epoetin alfa.
  5. I am generally well enough to participate in a study.
  6. My blood pressure is generally well-controlled.
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you decide to take part, you'll be assigned to receive either luspatercept or epoetin alfa. Neither you nor your doctor will get to choose which medicine you receive, and often you won't know which one it is (this is called a 'blinded' study). You'll have regular visits to the clinic for medical check-ups, blood tests, and to receive your study medicine. These visits will help the doctors monitor how you're doing, check your blood counts, and look for any side effects. The total duration of your participation in the study will depend on how you respond to the treatment and the study's design, but it will involve ongoing assessments and follow-up care.

المخاطر والفوائد المحتملة

Taking part in any medical study has potential benefits and risks. A potential benefit could be that the study medicine helps improve your anemia and reduces your need for blood transfusions. However, it's also possible that the study medicine may not work for you, or you might experience side effects. All medical treatments carry some level of risk. Your doctors will explain all known side effects for both medicines. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (226)

  • المؤسسة المحلية - 107
    الرمز البريدي المؤكد
    بيركلي، الولايات المتحدة
  • Local Institution - 115
    الرمز البريدي المؤكد
    سان دييغو، الولايات المتحدة
  • المؤسسة المحلية - 101
    الرمز البريدي المؤكد
    ويتيير، الولايات المتحدة
  • Local Institution - 104
    الرمز البريدي المؤكد
    نيو هيفن، الولايات المتحدة
  • Local Institution - 136
    الرمز البريدي المؤكد
    واشنطن العاصمة، الولايات المتحدة
  • Local Institution - 119
    الرمز البريدي المؤكد
    Hudson, United States
  • مؤسسة محلية - 120
    الرمز البريدي المؤكد
    سانت بطرسبرغ، الولايات المتحدة
  • مؤسسة محلية - 122
    الرمز البريدي المؤكد
    تالاهاسي، الولايات المتحدة
  • المؤسسة المحلية - 108
    الرمز البريدي المؤكد
    تامبا، الولايات المتحدة
  • Local Institution - 118
    الرمز البريدي المؤكد
    West Palm Beach, United States
  • المؤسسة المحلية - 102
    الرمز البريدي المؤكد
    بادوكا، الولايات المتحدة
  • Local Institution - 123
    الرمز البريدي المؤكد
    بيثيسدا، الولايات المتحدة

أسئلة شائعة

What is MDS?

MDS (Myelodysplastic Syndromes) is a condition where your bone marrow doesn't make enough healthy blood cells, often leading to low red blood cell counts and anemia.

What does 'transfusion independence' mean?

It means you no longer need regular blood transfusions because your body is making enough red blood cells on its own, or with the help of medication.

Why can't I choose which medicine I get?

In studies like this, treatments are often given randomly, and sometimes neither you nor your doctor knows which medicine you are receiving. This helps ensure the study results are fair and unbiased.

ماذا لو شعرت بآثار جانبية؟

The study team will closely monitor you for any side effects and will provide care and advice. You should always tell them about any new or worsening symptoms.

هل يمكنني مغادرة الدراسة في أي وقت؟

Yes, you have the right to withdraw from the study at any point, and this will not affect your future medical care.

كيفية معرفة المزيد

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.